Business
Hives Treatment Developer Third Harmonic Prices Upsized $185M IPO

Mikko Lemola
Hives treatment developer Third Harmonic Bio (THRD) has priced its upsized $185M initial public offering.
The biotech company said it now plans to offer 10.9M shares at $17 per share. Underwriters will be granted a 30-day option to buy up to 1.64M additional shares.
Morgan Stanley, Jefferies and Cowen are serving as joint bookrunners, with LifeSci Capital acting as co-manager.
Based in Cambridge, Mass., Third Harmonic’s lead product, THB001, is a KIT inhibitor being developed as a possible treatment for chronic uticaria, also known as hives.
The deal was upsized from an earlier proposal this month that had the company offering 9M shares priced between $16 and $18, which would have raised approximately $153M if priced at the midpoint.
Source Here: seekingalpha.com
Business
Oil and Gas Producer TXO Energy Sets Terms for Proposed $100M IPO
DariaRen
Oil and gas company MorningStar Partners, also known as TXO Energy Partners (TXO), has set terms for a proposed $100M initial public offering.
TXO said in its latest filing that it is now looking to offer 5M units, representing limited partners interests, priced between $19 and $21, which would raise $100M if priced at the midpoint. Proceeds from the deal would go in part to pay down debt.
The oil company hopes to list its shares on Nasdaq under the symbol TXO. Bookrunners include Raymond James, Stifel, Janney Montgomery Scott and Capital One Securities.
TXO first filed for an IPO in November, seeking $100M.
Based in Fort Worth, Texas, TXO is focused on acquiring, developing and exploiting oil and gas reserves, primarily in the Permian Basin of Texas and New Mexico and the San Juan Basin of New Mexico and Colorado.
TXO is one of several fossil fuel-associated companies that have filed to go public amid a global energy crisis. Other filers include BKV (BKV), Bounty Minerals (BNTY), Permex Petroleum (OTCQB:OILCF) and Elephant Oil (ELEP).
For more on TXO, check out Donovan Jones’s “TXO Energy Partners Starts IPO Process for Debt Paydown.”
Source Here: seekingalpha.com
Business
Hypertension Drug Developer Mineralys Therapeutics Files for $100M IPO
Andranik Hakobyan
Hypertension drug developer Mineralys Therapeutics (MLYS) has filed for a $100M initial public offering.
The biotech company didn’t specify in its filing the price or number of shares to be offered, but indicated in its filing fee schedule that it was seeking $100M, a figure that is likely a placeholder and subject to change.
Mineralys hopes to list its shares on Nasdaq under the symbol MLYS. Bookrunners include BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse and Wells Fargo Securities.
Based in Radnor, Penn., Mineralys is working on medications to treat diseases driven by abnormal levels of aldosterone. Its lead product, lorundrostat, is in Phase 2 testing for the treatment of uncontrolled hypertension and Phase 1 testing for chronic kidney disease.
Mineralys was the second biotech company to file for an IPO this week, with oral herpes drug developer Squarex Pharmaceuticals (SQRX) filing to raise $15M.
Original Article: seekingalpha.com
Business
Oil Extends Gains As China Optimism Outweighs Big Jump in U.S. Stockpiles
SlavkoSereda/iStock via Getty Images
U.S. crude oil advanced for the fifth straight session Wednesday, despite a U.S. government report showing a massive build in domestic crude inventories.
The Energy Information Administration reported U.S. crude stockpiles surged by 19M barrels – the third largest weekly increase since EIA records began in 1982 – which analysts said largely reflects the continued slower pace of refinery runs following shut-ins during last month’s winter storm.
But oil prices have enjoyed support in recent days from hopes for a strong rebound in Chinese demand, fears over the coming G-7 price cap on Russian refined products, and a weakening dollar.
Front-month Nymex February crude oil (CL1:COM) closed +3% to $77.41/bbl, while March Brent crude (CO1:COM) settled +3.2% to $82.67/bbl, its third consecutive gain.
ETFs: (NYSEARCA:USO), (BNO), (UCO), (SCO), (DBO), (DRIP), (GUSH), (USOI), (NRGU)
Analysts say oil markets are focused less on overall inventories and more on the global picture, which includes rising crude consumption in China, which has been snapping up cargoes of U.S. crude before the Lunar New Year holidays.
Earlier this week, the EIA forecast global liquid fuel consumption will top 100M bbl/day on average this year for the first time since 2019.
Original Source: seekingalpha.com
-
Business9 months ago
BHP’s Quarterly Australian Iron Ore Shipments Slipped 8%
-
Business9 months ago
Vale’s Q1 Profit Slides but Tops Estimates; Launches Big New Buyback Program
-
Business9 months ago
Muscular Dystrophy Drug Developer PepGen Files for $115M IPO
-
Business9 months ago
Robinhood Markets Q1 2022 Earnings Preview
-
Business9 months ago
Caesars Said to Seek Buyer for Flamingo Casino in Vegas for More Than $1B
-
Business9 months ago
Peru Declares Emergency in Bid to Restore Southern Copper’s Cuajone Mine
-
Business9 months ago
Gaming and Leisure Properties Q1 2022 Earnings Preview
-
Business9 months ago
Exxon Declares Force Majeure at Russia’s Sakhalin-1 Project